Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 10, 2015, Pages 1806-1814

  Stufano, F ^a   Baronciani, L ^a   Pagliari, M T ^a   Franchi, F ^b   Cozzi, G ^a   Garcia Oya, I ^a   Bucciarelli, P ^a   Boscarino, M ^a   Peyvandi, F ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

GPIbalpha protein, human; Ristocetin; Von Willebrand disease, type 2; Von Willebrand diseases; Von Willebrand factor

Indexed keywords

GLYCOPROTEIN IB; RISTOCETIN; VON WILLEBRAND FACTOR; ADHESION RECEPTOR; BIOLOGICAL MARKER; THROMBIN RECEPTOR;

AGGLUTINATION TEST; ARTICLE; BLOOD CLOTTING TEST; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODYNAMIC PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; PLATELET AGGREGATION ASSAY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISTOCETIN INDUCED PLATELET AGGLUTINATION ASSAY; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGLUTINATION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR ANTIGEN ASSAY; VON WILLEBRAND FACTOR GAIN OF FUNCTION MUTANT GLYCOPROTEIN IB BINDING ASSAY; VON WILLEBRAND FACTOR MUTANT GLYCOPROTEIN IB VON WILLEBRAND FACTOR RISTOCETIN COFACTOR RATIO; VON WILLEBRAND FACTOR RISTOCETIN COFACTOR ACTIVITY ASSAY; BLOOD; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; GENETICS; METABOLISM; MUTATION; PREDICTIVE VALUE; PROTEIN MULTIMERIZATION; SEVERITY OF ILLNESS INDEX; THROMBOCYTE; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE, TYPE 2;

BIOMARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MUTATION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PREDICTIVE VALUE OF TESTS; PROTEIN MULTIMERIZATION; RISTOCETIN; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND FACTOR;

EID: 84942984350     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13062     Document Type: Article

References (37)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
2. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake IR, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
3. Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease. Blood Rev 1999; 13: 185-204.
4. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-94.
5. Laffan M, Brown SA, Collins PW, Cumming AM, Hill FG, Keeling D, Peake IR, Pasi KJ. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 199-217.
6. James P, Lillicrap D. The role of molecular genetics in diagnosing von Willebrand disease. Semin Thromb Hemost 2008; 34: 502-8.
7. Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 1-12.
8. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibα to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 2004; 101: 10578-83.
9. Scaglione GL, Lancellotti S, Papi M, De Spirito M, Maiorana A, Baronciani L, Pagliari MT, Arcovito A, Di Stasio E, Peyvandi F, De Cristofaro R. The type 2B p. R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. J Thromb Haemost 2013; 11: 1688-98.
10. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302: 1047-51.
11. Scott JP, Montgomery RR. The rapid differentiation of type IIb von Willebrand's disease from platelet-type (pseudo-) von Willebrand's disease by the "neutral" monoclonal antibody binding assay. Am J Clin Pathol 1991; 96: 723-8.
12. Caron C, Hilbert L, Vanhoorelbeke K, Deckmyn H, Goudemand J, Mazurier C. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease. Br J Haematol 2006; 133: 655-63.
13. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21.
14. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011; 117: e67-74.
15. Bodo I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J, Subcommittee on von Willebrand factor. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13: 1345-50.
16. Federici AB, Canciani MT, Forza I, Mannucci PM, Marchese P, Ware J, Ruggeri ZM. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels. Haematologica 2004; 89: 77-85.
17. Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000). Blood Coagul Fibrinolysis 2004; 15: 505-11.
18. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent JA, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 1749-57.
19. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular characterization of a multiethnic group of 21 patients with type-3 von Willebrand disease. Thromb Haemost 2000; 84: 536-40.
20. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116: 280-6.
21. Schneppenheim R, Obser T, Budde U, Patzke J. Development of a newfunctional assay for von Willebrand factor binding to platelet GpIba that does not require ristocetin. Hamostaseologie 2010; 30: FC4-05.
22. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-13.
23. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, Pecci A, Lenting PJ, de Groot PG. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113: 526-34.
24. Weiss HJ, Sussman II. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood 1986; 68: 149-56.
25. Holmberg L, Berntorp E, Donner M, Nilsson IM. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood 1986; 68: 668-72.
26. Baronciani L, Federici AB, Beretta M, Cozzi G, Canciani MT, Mannucci PM. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost 2005; 3: 2689-94.
27. Casonato A, Sartorello F, Pontara E, Gallinaro L, Bertomoro A, Grazia CM, Daidone V, Szukowska M, Pagnan A. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis. Thromb Haemost 2007; 98: 1182-7.
28. Eikenboom JCJ, Vink T, Briët E, Sixma JJ, Reitsma PH. Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence. Proc Natl Acad Sci USA 1994; 91: 2221-4.
29. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood 2005; 106: 3035-42.
30. Tischer A, Madde P, Moon-Tasson L, Auton M. Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease. Biophys J 2014; 107: 1185-95.
31. De Cristofaro R, Peyvandi F, Baronciani L, Palla R, Lavoretano S, Lombardi R, Di Stasio E, Federici AB, Mannucci PM. Molecular mapping of the chloride-binding site in von Willebrand Factor (VWF) energetics and conformational effects on the VWF/ADAMTS-13 interaction. J Biol Chem 2006; 281: 30400-11.
32. Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the dagnosis of von Willebrand's disease. Pathology 1997; 29: 385-91.
33. Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009; 7: 1832-9.
34. Graf L, Moffat KA, Carlino SA, Chan AK, Iorio A, Giulivi A, Hayward CP. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. Int J Lab Hematol 2014; 36: 341-51.
35. Geisen U, Zieger B, Nakamura L, Weis A, Heinz J, Michiels JJ, Heilmann C. Comparison of von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo. Thromb Res 2014; 134: 246-50.
36. de Maistre E, Volot F, Mourey G, Aho LS, Ternisien C, Briquel ME, Bertrand MA, Tardy B, Frotscher B, Nguyen P, Dumont L, Vandroux D, Hezard N, Trossaert M. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance. Thromb Haemost 2014; 112: 825-30.
37. Patzke J, Budde U, Huber A, Mendez A, Muth H, Obser T, Peerschke E, Wilkens M, Schneppenheim R. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. Blood Coagul Fibrinolysis 2014; 25: 860-70.